Premium
Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding risk
Author(s) -
Collette Camille,
ClercUrmès Isabelle,
LabordeCastérot Hervé,
Frimat Luc,
Ayav Carole,
Peters Nicolas,
Martin Alexandre,
Agrinier Nelly,
Thilly Nathalie
Publication year - 2016
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.4002
Subject(s) - medicine , hemodialysis , hazard ratio , dialysis , medical prescription , anticoagulant , kidney disease , proportional hazards model , surgery , gastroenterology , confidence interval , pharmacology
Purpose Results of previous studies assessing the risk of bleeding associated with prescription of antiplatelet (AP) and/or oral anticoagulant (AC) therapy to hemodialysis patients are conflicting. Our purpose was to describe practices for prescription of AP and AC in hemodialysis patients in the Lorraine region, and to assess their effect on the risk of major bleeding events. Methods All adults with chronic kidney disease who began a first renal replacement therapy by hemodialysis in 2009 or 2010 in one of the 12 dialysis centers in Lorraine were included in the Thrombosis and Hemorrhage in HemoDialysis patients (T2HD) study and followed up until 30 June 2013. The association of each treatment (AP, AC, AP + AC) with the risk of major bleeding was estimated by three Cox proportional hazard models with an inverse probability of treatment weighting on a propensity score, considering the untreated patients as the reference. Results Among 502 patients included, 227 (45.2%) received an AP, 68 (13.5%) an AC, 81 (16.1%) a combination AP + AC, and 126 (25.1%) were untreated. As compared with untreated patients, those given AP (HR 5.52, 95% CI [3.11–9.80]), AC (HR: 4.15, 95% CI: [3.46–4.99]), and AP + AC (HR: 5.59, 95% CI [2.62–11.91]) were at greater risk of major bleeding events. Conclusions The risk of major bleeding is higher in patients receiving an oral AC compared with untreated patients and those receiving an AP agent. A combination of the two drugs does not seem to increase the risk. Copyright © 2016 John Wiley & Sons, Ltd.